Clinical trial · no report yet · Phase 3
INTerpath-002
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06077760 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Intismeran autogene; Pembrolizumab; Placebo
- Arms
- Intismeran autogene + Pembrolizumab · Experimental
- Placebo + Pembrolizumab · Active comparator
- Enrollment
- 868 (estimated)
- Primary outcomes
- Disease- Free Survival (DFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Dec 6, 2023
- Primary completion
- Jun 25, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06077760 · updated Sep 18, 2026